AzTrials
AzTrials

Acute Heart FailureREPORT-HFNCT02595814

Global Non-interventional Heart Failure Disease Registry

An observational study of Acute Heart Failure, run by Novartis Pharmaceuticals at 346 sites in 44 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Heart Failure
How many people
18,805 participants
Where
346 sitesin 44 countries
Study dates
23 Jul 2014to 31 Mar 2018
How long will I take part?
3 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Enrollment of adult patients hospitalized with a primary diagnosis of acute Heart Failure (HF), i.e. new-onset (first diagnosis) HF or decompensation of chronic HF

Who may be able to join

  • Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure.

Who cannot join

  • 1-Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor).
  • 2. Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

Trial locations and contacts

346 sites in 44 countries.

346 sites in 44 countries

China29 sites

  • Novartis Investigative Site

    Baotou, Inner Mongolia, 014040

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100044

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100191

  • Novartis Investigative Site

    Beijing, 100022

  • Novartis Investigative Site

    Beijing, 100029

  • Novartis Investigative Site

    Beijing, 100034

  • Novartis Investigative Site

    Beijing, 100053

  • Novartis Investigative Site

    Beijing

  • Novartis Investigative Site

    Changchun, Jilin, 130021

  • Novartis Investigative Site

    Changsha, Hunan, 410005

  • Novartis Investigative Site

    Changsha, Hunan, 410011

  • Novartis Investigative Site

    Dalian, Liaoning, 116011

  • Novartis Investigative Site

    Fuzhou, Fujian

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080

  • Novartis Investigative Site

    Guangzhou, 510260

  • Novartis Investigative Site

    Hangzhou, 310006

  • Novartis Investigative Site

    Jinan, 250012

  • Novartis Investigative Site

    Luoyang, 471000

  • Novartis Investigative Site

    Shanghai, 200080

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050000

  • Novartis Investigative Site

    Taiyuan

  • Novartis Investigative Site

    Ürümqi, 830000

  • Novartis Investigative Site

    Ürümqi, 830054

  • Novartis Investigative Site

    Wuhan, Hubei, 430074

  • Novartis Investigative Site

    Wuhan, 430022

  • Novartis Investigative Site

    Xiamen, 361004

  • Novartis Investigative Site

    Yangzhou, 225001

  • Novartis Investigative Site

    Zhengzhou, 450003

  • Novartis Investigative Site

    Zhengzhou

Other trials in China

India25 sites

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380 060

  • Novartis Investigative Site

    Amritsar, Punjab, 143004

  • Novartis Investigative Site

    Bangalore, Karnataka, 560 069

  • Novartis Investigative Site

    Bangalore, Karnataka, 560099

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600037

  • Novartis Investigative Site

    Gurgaon, Haryana, 122001

  • Novartis Investigative Site

    Hyderabad, Telangana, 500034

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082

  • Novartis Investigative Site

    India, 560040

  • Novartis Investigative Site

    Kolkata, West Bengal, 700 107

  • Novartis Investigative Site

    Kolkata, West Bengal, 700099

  • Novartis Investigative Site

    Ludhiana, Punjab, 141001

  • Novartis Investigative Site

    Ludhiana, Punjab, 141008

  • Novartis Investigative Site

    Manipal, Karnataka, 576104

  • Novartis Investigative Site

    Mumbai, 400053

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440008

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110 060

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110017

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110070

  • Novartis Investigative Site

    New Delhi, 110002

  • Novartis Investigative Site

    New Delhi, 110025

  • Novartis Investigative Site

    Panjim, Goa, 403001

  • Novartis Investigative Site

    Pune, Maharashtra, 411 011

  • Novartis Investigative Site

    Pune, Maharashtra, 411011

  • Novartis Investigative Site

    Vadodara, Gujarat, 390022

Other trials in India

Russia18 sites

  • Novartis Investigative Site

    Kazan', 420033

  • Novartis Investigative Site

    Kemerovo, 654005

  • Novartis Investigative Site

    Krasnodar, 350086

  • Novartis Investigative Site

    Moscow, 117292

  • Novartis Investigative Site

    Moscow, 127473

  • Novartis Investigative Site

    Novosibirsk, 630091

  • Novartis Investigative Site

    Ryazan, 390026

  • Novartis Investigative Site

    S-Petersburg, 194354

  • Novartis Investigative Site

    Saint Petersburg, 191015

  • Novartis Investigative Site

    Saint Petersburg, 194044

  • Novartis Investigative Site

    Saint Petersburg, 197341

  • Novartis Investigative Site

    Saratov, 410004

  • Novartis Investigative Site

    Saratov, 410017

  • Novartis Investigative Site

    Stavropol, 355030

  • Novartis Investigative Site

    Tyumen, 625023

  • Novartis Investigative Site

    Ulyanovsk, 432057

  • Novartis Investigative Site

    Vladivostok, 690002

  • Novartis Investigative Site

    Volgograd, 400026

Other trials in Russia

United States15 sites

  • Novartis Investigative Site

    Chicago, Illinois, 60611

  • Novartis Investigative Site

    Cincinnati, Ohio, 45267

  • Novartis Investigative Site

    Dallas, Texas, 75390

  • Novartis Investigative Site

    Detroit, Michigan, 48201

  • Novartis Investigative Site

    Detroit, Michigan, 48202

  • Novartis Investigative Site

    Indianapolis, Indiana, 46202

  • Novartis Investigative Site

    Jackson, Mississippi, 39216

  • Novartis Investigative Site

    Kansas City, Kansas, 66160

  • Novartis Investigative Site

    Nashville, Tennessee, 37203

  • Novartis Investigative Site

    New Orleans, Louisiana, 70112

  • Novartis Investigative Site

    New Orleans, Louisiana, 70121

  • Novartis Investigative Site

    New York, New York, 10029

  • Novartis Investigative Site

    San Diego, California, 92103

  • Novartis Investigative Site

    San Francisco, California, 94143-0780

  • Novartis Investigative Site

    Stony Brook, New York, 11794

Other trials in United States

Argentina15 sites

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires F.D., 1118

  • Novartis Investigative Site

    Buenos Aires, C1094AAD

  • Novartis Investigative Site

    Buenos Aires, C1426EOB

  • Novartis Investigative Site

    Buenos Aires

  • Novartis Investigative Site

    CABA, Buenos Aires, C1181ACH

  • Novartis Investigative Site

    CABA, Buenos Aires, C1210AAP

  • Novartis Investigative Site

    Córdoba, X5000JHQ

  • Novartis Investigative Site

    Córdoba, X5000

  • Novartis Investigative Site

    Coronel Suarez, Buenos Aires F.D., 7540

  • Novartis Investigative Site

    Corrientes, W3400AFT

  • Novartis Investigative Site

    Mendoza, M5500AAJ

  • Novartis Investigative Site

    Resistencia, Chaco Province, H3500CDM

  • Novartis Investigative Site

    Rosario, Santa Fe Province, 2000

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000DSV

  • Novartis Investigative Site

    Salta, 4000

Other trials in Argentina

Germany13 sites

  • Novartis Investigative Site

    Berlin, 13353

  • Novartis Investigative Site

    Bonn, 53105

  • Novartis Investigative Site

    Essen, 45356

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106

  • Novartis Investigative Site

    Göttingen, 37075

  • Novartis Investigative Site

    Halle, 06120

  • Novartis Investigative Site

    Hanover, 30625

  • Novartis Investigative Site

    Heidelberg, 69120

  • Novartis Investigative Site

    Homburg, 66421

  • Novartis Investigative Site

    Lübeck, 23538

  • Novartis Investigative Site

    Ludwigshafen, 67063

  • Novartis Investigative Site

    Nuremberg, 90471

  • Novartis Investigative Site

    Würzburg, 97078

Other trials in Germany

Spain13 sites

  • Novartis Investigative Site

    Alicante, Valencia, 03010

  • Novartis Investigative Site

    Barakaldo, Basque Country, 48903

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035

  • Novartis Investigative Site

    Barcelona, Catalonia, 08036

  • Novartis Investigative Site

    Barcelona, 08041

  • Novartis Investigative Site

    Córdoba

  • Novartis Investigative Site

    Las Palmas de Gran Canaria, Las Palmas de G.C, 35020

  • Novartis Investigative Site

    León, 24080

  • Novartis Investigative Site

    Majadahonda, Madrid, 28222

  • Novartis Investigative Site

    Mallorca, Balearic Islands, 07198

  • Novartis Investigative Site

    Mérida, Extremadura, 06800

  • Novartis Investigative Site

    Murcia, 30008

  • Novartis Investigative Site

    Tarragona, Catalonia, 43005

Other trials in Spain

Greece11 sites

  • Novartis Investigative Site

    Athens, GR, 115 25

  • Novartis Investigative Site

    Athens, GR, 115 27

  • Novartis Investigative Site

    Athens, GR, 11527

  • Novartis Investigative Site

    Athens, 11526

  • Novartis Investigative Site

    Athens, 54642

  • Novartis Investigative Site

    Athens, GR 115 22

  • Novartis Investigative Site

    Glyfada, 16675

  • Novartis Investigative Site

    Ioannina, 45100

  • Novartis Investigative Site

    Piraeus, 18454

  • Novartis Investigative Site

    Thessaloniki, GR, 570 10

  • Novartis Investigative Site

    Thessaloniki, 54642

Other trials in Greece

South Korea11 sites

  • Novartis Investigative Site

    Busan, 612-896

  • Novartis Investigative Site

    Cheongju-si, North Chungcheong, 28644

  • Novartis Investigative Site

    Daejeon, Korea, 301-721

  • Novartis Investigative Site

    Gyeonggi-do, Bucheon-si, 422-711

  • Novartis Investigative Site

    Incheon, 403-720

  • Novartis Investigative Site

    Pusan, 614-735

  • Novartis Investigative Site

    Seoul, 07061

  • Novartis Investigative Site

    Seoul, 136-705

  • Novartis Investigative Site

    Suwon, 16247

  • Novartis Investigative Site

    Taegu, 700 -721

  • Novartis Investigative Site

    Wŏnju, Gangwon-do, 220-701

Other trials in South Korea

Brazil10 sites

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, 30130-100

  • Novartis Investigative Site

    Campinas, São Paulo, 13060-904

  • Novartis Investigative Site

    Curitiba, Paraná, 80010-030

  • Novartis Investigative Site

    Curitiba

  • Novartis Investigative Site

    Fortaleza, Ceará, 60864-190

  • Novartis Investigative Site

    Recife

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, 22280-020

  • Novartis Investigative Site

    Rio de Janeiro

  • Novartis Investigative Site

    Sao Jose Do Rico Preto

  • Novartis Investigative Site

    Tatuí, São Paulo, 18270-170

Other trials in Brazil

Turkey (Türkiye)10 sites

  • Novartis Investigative Site

    Ankara, 06100

  • Novartis Investigative Site

    Ankara, 06590

  • Novartis Investigative Site

    Bursa, 16059

  • Novartis Investigative Site

    Bursa

  • Novartis Investigative Site

    Diskapi / Ankara, 06110

  • Novartis Investigative Site

    Haydarpasa/Istanbul, 34668

  • Novartis Investigative Site

    Istanbul, 34093

  • Novartis Investigative Site

    Meselik / Eskisehir, 26480

  • Novartis Investigative Site

    Pendik / Istanbul, Turkey, 34899

  • Novartis Investigative Site

    Sivas, 58140

Other trials in Turkey (Türkiye)

United Kingdom10 sites

  • Novartis Investigative Site

    Bradford, West Yorkshire, BD9 6RJ

  • Novartis Investigative Site

    Chesterfield, Yorkshire, S44 5BL

  • Novartis Investigative Site

    Chesterfield, BS1 3NU

  • Novartis Investigative Site

    Edgbaston, Birmingham, B15 2WB

  • Novartis Investigative Site

    Herts, Yorkshire, SG1 4AB

  • Novartis Investigative Site

    Stockton-on-Tees, Cleveland, TS19 8PE

  • Novartis Investigative Site

    Telford, TF1 6TF

  • Novartis Investigative Site

    Uxbridge, UB8 3NN

  • Novartis Investigative Site

    Wakefield, WF1 4DG

  • Novartis Investigative Site

    York, YO31 8HE

Other trials in United Kingdom

Colombia9 sites

  • Novartis Investigative Site

    Armenia

  • Novartis Investigative Site

    Barranquilla, Atlántico

  • Novartis Investigative Site

    Bogotá, Cundinamarca, 110111

  • Novartis Investigative Site

    Bogotá, 00000

  • Novartis Investigative Site

    Bogotá

  • Novartis Investigative Site

    Bucaramanga, Santander Department

  • Novartis Investigative Site

    Cali

  • Novartis Investigative Site

    Medellín, Antioquia, 0050010

  • Novartis Investigative Site

    Medellín, Antioquia

Other trials in Colombia

Indonesia9 sites

  • Novartis Investigative Site

    Bandung, West Java, 40161

  • Novartis Investigative Site

    Bekasi, West Java, 17144

  • Novartis Investigative Site

    East Jakarta, DKI Jakarta, 13630

  • Novartis Investigative Site

    Medan, North Sumatera, 20136

  • Novartis Investigative Site

    Padang, West Sumatra, 25127

  • Novartis Investigative Site

    South Jakarta, DKI Jakarta, 12430

  • Novartis Investigative Site

    Surabaya, East Java, 60286

  • Novartis Investigative Site

    Tangerang, Banten, 15111

  • Novartis Investigative Site

    West Jakarta, DKI Jakarta, 11420

Other trials in Indonesia

Mexico9 sites

  • Novartis Investigative Site

    Aguascalientes, 20230

  • Novartis Investigative Site

    Culiacán, Sinaloa SN, 80230

  • Novartis Investigative Site

    Mexico City, Mexico City, 03100

  • Novartis Investigative Site

    Mexico City, Mexico City, 06090

  • Novartis Investigative Site

    Mexico City, Mexico City, 14080

  • Novartis Investigative Site

    San Luis Potosí City, 78213

  • Novartis Investigative Site

    San Luis Potosí City, 78240

  • Novartis Investigative Site

    Xalapa, 91020

  • Novartis Investigative Site

    Xalapa, 91193

Other trials in Mexico

Romania8 sites

  • Novartis Investigative Site

    Bucharest, 022322

  • Novartis Investigative Site

    Bucharest, 030 171

  • Novartis Investigative Site

    Buzău, 120140

  • Novartis Investigative Site

    Cluj-Napoca, Napoca, 400006

  • Novartis Investigative Site

    Cluj-Napoca, 400006

  • Novartis Investigative Site

    Focşani, 620034

  • Novartis Investigative Site

    Lasi, 700075

  • Novartis Investigative Site

    Timișoara, 300054

Other trials in Romania

Japan7 sites

  • Novartis Investigative Site

    Chiyoda-ku, Tokyo, 101-8643

  • Novartis Investigative Site

    Hirakata, Osaka, 573-0153

  • Novartis Investigative Site

    Kita-ku, Okayama-ken, 7000084

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 802-8555

  • Novartis Investigative Site

    Kure, Hiroshima, 737-0023

  • Novartis Investigative Site

    Nagasaki, 850-8555

  • Novartis Investigative Site

    Sakaidechō, Kagawa-ken, 762-0007

Other trials in Japan

Philippines7 sites

  • Novartis Investigative Site

    Angeles City, Pampanga, 2009

  • Novartis Investigative Site

    Baguio City, Baguio, 2600

  • Novartis Investigative Site

    Cagayan de Oro City, Cagayan Valley, 9000

  • Novartis Investigative Site

    Cebu City, Cebu, 6000

  • Novartis Investigative Site

    Davao City, Davao Region, 8000

  • Novartis Investigative Site

    Manila, National Capital Region, 1000

  • Novartis Investigative Site

    Quezon City, Manila, 1100

Other trials in Philippines

Thailand7 sites

  • Novartis Investigative Site

    Bangkok, 10310

  • Novartis Investigative Site

    Bangkok, 10400

  • Novartis Investigative Site

    Chiang Mai, 50200

  • Novartis Investigative Site

    Khon Kaen, THA, 40002

  • Novartis Investigative Site

    Muang, Muang, 65000

  • Novartis Investigative Site

    Muang, Thailand, 12120

  • Novartis Investigative Site

    Muang, Thailand, 30000

Other trials in Thailand

Bulgaria6 sites

  • Novartis Investigative Site

    Pleven, 5800

  • Novartis Investigative Site

    Plovdiv, 4002

  • Novartis Investigative Site

    Sofia, 1202

  • Novartis Investigative Site

    Sofia, 1527

  • Novartis Investigative Site

    Sofia, 1606

  • Novartis Investigative Site

    Varna, 9010

Other trials in Bulgaria

Lebanon6 sites

  • Novartis Investigative Site

    Beirut, 1107 2020

  • Novartis Investigative Site

    Beirut, 6301

  • Novartis Investigative Site

    Beirut

  • Novartis Investigative Site

    Byblos

  • Novartis Investigative Site

    El Chouf, LBN

  • Novartis Investigative Site

    Saida, 652

Other trials in Lebanon

Netherlands6 sites

  • Novartis Investigative Site

    Amsterdam, 1034CS

  • Novartis Investigative Site

    Groningen, 9713 GZ

  • Novartis Investigative Site

    Leiderdorp, NL-2353 GA

  • Novartis Investigative Site

    Sneek, 8601ZK

  • Novartis Investigative Site

    Venlo, 5912 BL

  • Novartis Investigative Site

    Zwolle, 8025 AB

Other trials in Netherlands

Sweden6 sites

  • Novartis Investigative Site

    Gothenburg, 416 85

  • Novartis Investigative Site

    Helsingborg, 252 20

  • Novartis Investigative Site

    Karlshamn, 37480

  • Novartis Investigative Site

    Linköping, 581 85

  • Novartis Investigative Site

    Malmö, 205 20

  • Novartis Investigative Site

    Trollhättan, 46173

Other trials in Sweden

Taiwan6 sites

  • Novartis Investigative Site

    Linkou District, 33305

  • Novartis Investigative Site

    Taichung, 40705

  • Novartis Investigative Site

    Tainan, 70421

  • Novartis Investigative Site

    Taipei, 10002

  • Novartis Investigative Site

    Taipei, 110

  • Novartis Investigative Site

    Taipei, 11217

Other trials in Taiwan

Austria5 sites

  • Novartis Investigative Site

    Eisenstadt, 7000

  • Novartis Investigative Site

    Linz, 4021

  • Novartis Investigative Site

    Mödling, A-2340

  • Novartis Investigative Site

    Vienna, A-1160

  • Novartis Investigative Site

    Vienna, A-1220

Other trials in Austria

Canada5 sites

  • Novartis Investigative Site

    Edmonton, Alberta, T6G 2B7

  • Novartis Investigative Site

    Halifax, Nova Scotia, B3H 3A7

  • Novartis Investigative Site

    Ottawa, Ontario, K1Y 4W7

  • Novartis Investigative Site

    Sainte-Foy, Quebec, G1V 4G5

  • Novartis Investigative Site

    Vancouver, British Columbia, V6Z 1Y6

Other trials in Canada

Egypt5 sites

  • Novartis Investigative Site

    Alexandria, 21411

  • Novartis Investigative Site

    Cairo, 11566

  • Novartis Investigative Site

    Cairo

  • Novartis Investigative Site

    El Menia, Upper Egypt

  • Novartis Investigative Site

    Suez Canal Region, 41111

Other trials in Egypt

Israel5 sites

  • Novartis Investigative Site

    Jerusalem, 91031

  • Novartis Investigative Site

    Jerusalem, 91240

  • Novartis Investigative Site

    Kfar Saba, 4428164

  • Novartis Investigative Site

    Nazareth, 16100

  • Novartis Investigative Site

    Sefad, 13100

Other trials in Israel

Jordan5 sites

  • Novartis Investigative Site

    Amman, 11121

  • Novartis Investigative Site

    Amman, 11196

  • Novartis Investigative Site

    Amman, 11942

  • Novartis Investigative Site

    Amman

  • Novartis Investigative Site

    Irbid, 22110

Other trials in Jordan

Malaysia5 sites

  • Novartis Investigative Site

    Alor Star, Kedah, 05460

  • Novartis Investigative Site

    Johor Bahru, 80100

  • Novartis Investigative Site

    Kota Bharu, Kelantan, 16150

  • Novartis Investigative Site

    Kuala Lumpur, 50586

  • Novartis Investigative Site

    Pulau Pinang, Pulau Pinang, 10990

Other trials in Malaysia

Saudi Arabia5 sites

  • Novartis Investigative Site

    Al Ahsa

  • Novartis Investigative Site

    Dammam, 15215

  • Novartis Investigative Site

    Dammam, 31463

  • Novartis Investigative Site

    Khamis Mushait, 62413

  • Novartis Investigative Site

    Riyadh, 3643

Other trials in Saudi Arabia

South Africa5 sites

  • Novartis Investigative Site

    Bloemfontein, 9301

  • Novartis Investigative Site

    Cape Town, 7405

  • Novartis Investigative Site

    Cape Town, 7505

  • Novartis Investigative Site

    Durban, KwaZulu-Natal, 4052

  • Novartis Investigative Site

    Rivonia, 2128

Other trials in South Africa

Tunisia5 sites

  • Novartis Investigative Site

    Monastir, 5000

  • Novartis Investigative Site

    Sousse, 4011

  • Novartis Investigative Site

    Tunis, 1006

  • Novartis Investigative Site

    Tunis, 1007

  • Novartis Investigative Site

    Tunis, 1008

Other trials in Tunisia

Algeria4 sites

  • Novartis Investigative Site

    Algiers, 16000

  • Novartis Investigative Site

    Algiers, 16040

  • Novartis Investigative Site

    Algiers, 16206

  • Novartis Investigative Site

    Oran, 31000

Other trials in Algeria

Australia4 sites

  • Novartis Investigative Site

    Auchenflower, Queensland, 4066

  • Novartis Investigative Site

    Bedford Park, SA 5042

  • Novartis Investigative Site

    Gosford, New South Wales, 2250

  • Novartis Investigative Site

    Greenslopes, Queensland, 4120

Other trials in Australia

Chile4 sites

  • Novartis Investigative Site

    Concepción

  • Novartis Investigative Site

    San Miguel, Santiago Metropolitan, 8900000

  • Novartis Investigative Site

    Santiago, Piso 1

  • Novartis Investigative Site

    Santiago

Other trials in Chile

Ecuador4 sites

  • Novartis Investigative Site

    Guayaquil, Guayas

  • Novartis Investigative Site

    Guayaquil

  • Novartis Investigative Site

    Portoviejo

  • Novartis Investigative Site

    Quito, Pichincha, 1701

Other trials in Ecuador

United Arab Emirates4 sites

  • Novartis Investigative Site

    Abu Dhabi, 51900

  • Novartis Investigative Site

    Al Ain City

  • Novartis Investigative Site

    Dubai, 7272

  • Novartis Investigative Site

    Dubai

Other trials in United Arab Emirates

Morocco3 sites

  • Novartis Investigative Site

    Casablanca

  • Novartis Investigative Site

    Marrakesh, 40 000

  • Novartis Investigative Site

    Rabat, 10 000

Other trials in Morocco

Norway3 sites

  • Novartis Investigative Site

    Hønefoss, 3501

  • Novartis Investigative Site

    Oslo, 370

  • Novartis Investigative Site

    Skien, NO-3710

Other trials in Norway

Switzerland3 sites

  • Novartis Investigative Site

    Basel, 4031

  • Novartis Investigative Site

    Bruderholz, 4101

  • Novartis Investigative Site

    Zurich, 8032

Other trials in Switzerland

Guatemala2 sites

  • Novartis Investigative Site

    Guatemala City, 01011

  • Novartis Investigative Site

    Guatemala City

Other trials in Guatemala

Panama2 sites

  • Novartis Investigative Site

    Panama City

  • Novartis Investigative Site

    San Jose de David, Provincia de Panamá

Other trials in Panama

Vietnam2 sites

  • Novartis Investigative Site

    Ho Chi Minh City, District 7

  • Novartis Investigative Site

    Ho Chi Minh City

Other trials in Vietnam

About this study

Official title: International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

Keywords
Registry, Heart failure, Hospitalized, Global, Morbidity, Mortality, Quality of life, AHF
Medical subject headings
Heart Failure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients with different characteristics of heart faliure (HF) at hospitalization

    Measured: From admission to discharge of the patient's index hospitalization (minimum 24 hours)

  2. Percentage of patients who die during the index hospitalization

    Measured: From admission to discharge of the patient's index hospitalization (minimum 24 hours)

  3. Percentage of patients who die during the follow-up period post-discharge

    Measured: up to 3 years

  4. Percentage of patients who are re-hospitalized by primary re-hospitalization reason (Cardiovascular and non-Cardiovascular)

    Measured: up to 3 years

  5. Number of patients with different characteristics of post-discharge patient management

    Measured: up to 3 years

  6. Healthcare Resource Utilization assessed by number of patients with re-hospitalizations

    Measured: up to 3 years

Secondary outcomes (3)

  1. Health-related Quality of life (HRQoL) based on patient reported data as measured by EQ-5D and the Kansas City Cardiomyopathy Questionnaire (KCCQ) questionnaires

    Measured: up to 3 years

  2. Caregiver burden based on Caregiver Burden Questionnaire -Heart Failure (CBQ-HF) and Work Productivity and Activity Impairment (WPAI) questionnaires

    Measured: up to 3 years

  3. Correlation ratio between practice patterns and outcomes

    Measured: up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2015 (estimated)
  2. Study start23 Jul 2014
  3. Primary completion31 Mar 2018
  4. Study completion31 Mar 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
18,805 participants (actual)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT02595814
Sponsor's protocol ID
CRPORTHF
Acronym
REPORT-HF
Status last verified
Nov 2018
First submitted
13 Oct 2015
Last updated
14 Nov 2018
Results posted
No
Data monitoring committee
No

Publications

  • Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, Angermann CE, Ertl G, Dahlstrom U, Hu D, Dickstein K, Perrone SV, Ghadanfar M, Bermann G, Noe A, Schweizer A, Maier T, Gheorghiade M. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May;17(5):527-33. doi: 10.1002/ejhf.262. Epub 2015 Mar 10.

    PubMed 25754836

  • Tay WT, Teng TK, Ouwerkerk W, Cleland JGF, Collins SP, Angermann CE, Dickstein K, Dahlstrom U, Schweizer A, Obergfell A, Yiu KH, Ghadanfar M, Hassanein M, Ren QW, Gu WL, Ertl G, Perrone SV, Filippatos G, Lam CSP, Tromp J. Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry. Eur J Heart Fail. 2025 Dec;27(12):2705-2715. doi: 10.1002/ejhf.70056. Epub 2025 Oct 1.

    PubMed 41031485

  • Chyou JY, Tay WT, Tromp J, Ouwerkerk W, Yiu KH, Cleland JGF, Collins SP, Angermann CE, Ertl G, Dahlstrom U, Dickstein K, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Filippatos G, Lam CSP. Prognostic Implications and Global Perspectives of Atrial Fibrillation in Patients Hospitalized for Heart Failure. JACC Heart Fail. 2025 Mar;13(3):453-464. doi: 10.1016/j.jchf.2024.11.009. Epub 2025 Feb 5.

    PubMed 39918534

  • Ouwerkerk W, Tromp J, Cleland JGF, Angermann CE, Dahlstrom U, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Dickstein K, Filippatos G, Collins SP, Lam CSP. Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. Eur J Heart Fail. 2023 Jan;25(1):43-51. doi: 10.1002/ejhf.2708. Epub 2022 Nov 23.

    PubMed 36196060

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Heart Failure, run by Novartis Pharmaceuticals at 346 sites in 44 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 14 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 346 sites in China, India, Russia, United States, Argentina and 39 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early. Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients with different characteristics of heart faliure (HF) at hospitalization (time frame: From admission to discharge of the patient's index hospitalization (minimum 24 hours)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02595814, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2018; AzTrials last refreshed its copy on 31 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in